Toward Resolving the Challenges of Sepsis Diagnosis
Open Access
- 1 August 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 50 (8) , 1301-1314
- https://doi.org/10.1373/clinchem.2004.032144
Abstract
Sepsis in the United States has an estimated annual healthcare cost of $16.7 billion and leads to 120 000 deaths. Insufficient development in both medical diagnosis and treatment of sepsis has led to continued growth in reported cases of sepsis over the past two decades with little improvement in mortality statistics. Efforts over the last decade to improve diagnosis have unsuccessfully sought to identify a “magic bullet” proteic biomarker that provides high sensitivity and specificity for infectious inflammation. More recently, genetic methods have made tracking regulation of the genes responsible for these biomarkers possible, giving current research new direction in the search to understand how host immune response combats infection. Despite the breadth of research, inadequate treatment as a result of delayed diagnosis continues to affect approximately one fourth of septic patients. In this report we review past and present diagnostic methods for sepsis and their respective limitations, and discuss the requirements for more timely diagnosis as the next step in curtailing sepsis-related mortality. We also present a proposal toward revision of the current diagnostic paradigm to include real-time immune monitoring.Keywords
This publication has 112 references indexed in Scilit:
- Molecular Characterization of the Acute Inflammatory Response to Infections with Gram-Negative versus Gram-Positive BacteriaInfection and Immunity, 2003
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- Enhanced surface plasmon resonance immunoassay for human complement factor 4Analytica Chimica Acta, 2002
- Stereotyped and specific gene expression programs in human innate immune responses to bacteriaProceedings of the National Academy of Sciences, 2002
- Human macrophage activation programs induced by bacterial pathogensProceedings of the National Academy of Sciences, 2002
- Genetic Markers in SepsisJournal of the American College of Surgeons, 2001
- Outcome Prediction by Traditional and New Markers of Inflammation in Patients with Sepsiscclm, 1999
- Antiinflammatory Cytokine Responses during Clinical Sepsis and Experimental Endotoxemia: Sequential Measurements of Plasma Soluble Interleukin (IL)-1 Receptor Type II, IL-10, and IL-13The Journal of Infectious Diseases, 1997
- Diagnostic value of plasma levels of tumor necrosis factor α (TNFα) and interleukin‐6 (IL‐6) in newborns with sepsisActa Paediatrica, 1994
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992